The SYNTap Test helps physicians diagnose synucleinopathies such as: Parkinson’s, LBD, Alzheimer’s with Lewy Bodies, MCI, and MSA.
This website is intended for the informational purposes of healthcare professionals.
How the SYNTap Test helps improve diagnostic accuracy for various types of Parkinson's.
How the SYNTap Test can improve the diagnostic challenges of Lewy Body Dementia.
How the SYNTap Test helps differentiate the Alzheimer's variant: AD with Lewy Bodies.
How the SYNTap Test helps physicians differentiate MSA from Parkinson's disease.
How the SYNTap Test helps detect Minimal Cognitive Impairment with Lewy Bodies early.
Details on the SYNTap Biomarker Test performance characteristics.
A pioneer of Prion Detection Science®, Amprion innovates biomarker testing to accurately detect misfolded proteins associated with brain diseases.
After decades of research, Amprion is thrilled to rollout its impactful discoveries from the lab to the world.
San Francisco Amprion, a leader in diagnostics for
Amprion is pleased to announce a research collaboration
Thanks to additional research funding from NIH/NINDS, Amprion
A pioneer in the science of detecting mis-folded proteins, Amprion advances the diagnosis of brain disorders. Our SYNTap™️ Biomarker Test aids physicians in diagnosing Parkinson’s, Lewy Body Dementia, and Alzheimer’s with Lewy Body variant. We plan to launch more biomarker tests in the future.
Amprion has some important news we need to share with you!
To improve patient access to the SYNTap® biomarker test (CSF), Amprion is reducing the self-pay price for tests with service dates on or after July 1, 2023.
Old self-pay price: $1500.00. New self-pay price: $995.00
Effective July 1, 2023, there is a New ABN (Advanced Beneficiary Notification) form for use when ordering the SYNTap® biomarker test (CSF) for patients on Medicare. Order Process
